The challenge of cardiovascular diseases in HIV-positive patients: It's time for redrawing the maps of cardiovascular risk?

International Journal of Clinical Practice

Volumn 67, Issue 1, 2013, Pages 1-3

  Ceccarelli, G ^a   D'Ettorre, G ^a   Vullo, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; COMORBIDITY; CORONARY ARTERY ATHEROSCLEROSIS; FRAMINGHAM RISK SCORE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; MORBIDITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; COINFECTION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE;

EID: 84871414975     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12066     Document Type: Review

References (21)

1. Hakeem A, Bhatti S, Cilingiroglu M,. The spectrum of atherosclerotic coronary artery disease in HIV patients. Curr Atheroscler Rep 2010; 12: 119-24.
2. Friis-Møller N, Thiébaut R, Reiss P, et al., Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on Adverse Effects of Anti-HIV Drugs Study. Eur J Cardiovasc Prev Rehabil 2010; 17: 491-501.
3. Moreira Guimarøes MM, Bartolomeu Greco D, Ingles Garces AH, de Oliveira AR Jr, Bastos Fõscolo R, de Campos Machado LJ, Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions. Int J Clin Pract 2010; 64: 739-45.
4. Monteiro VS, Lacerda HR, Uellendahl M, et al., Calcium score in the evaluation of atherosclerosis in patients with HIV/AIDS. Arq Bras Cardiol 2011; 97: 427-33.
5. d'Ettorre G, Francone M, Mancone M, et al., Significant coronary stenosis detected by coronary computer angiography in asymptomatic HIV infected subjects. J Infect 2012; 64: 82-8.
6. European AIDS Clinical Society (EACS) Guidelines (Version 6-October 2011). http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/ EACSGuidelines-v6.0-English.pdf (Accessed 15 October 2012).
7. Italian Guidelines for the use of antiretroviral drugs and the diagnostic-clinical management of people with HIV-1 infection (October 2011). http://www.salute.gov.it/imgs/C-17-pubblicazioni-1301-allegato.pdf (Accessed 15 October 2012).
8. Antinori A, Marcotullio S, Ammassari A, et al., Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol 2011; 34: 109-46.
9. Antinori A, Marcotullio S, Ammassari A, et al., Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol 2012; 35: 113-59.
10. Ceccarelli G, d'Ettorre G, Mancone M, et al., Accelerated coronary atherosclerosis after execution of percutaneous coronary intervention in patient with HIV/HCV coinfection: case report and review of the literature. Cardiovasc Revasc Med 2011; 12: 262-5.
11. Martínez E, Larrousse M, Gatell JM,. Cardiovascular disease and HIV infection: host, virus, or drugs? Curr Opin Infect Dis 2009; 22: 28-34.
12. Arildsen H, Sørensen K, Ingerslev J, Ostergaard L, Laursen A,. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 2012; [Epub ahead of print]. doi: 10.1111/j.1468-1293.2012. 01027.x.
13. Casaretti L, Paolillo S, Formisano R, et al., Metabolic and cardiovascular effects of combined antiretroviral therapy in patients with HIV infection. Systematic review of literature. Monaldi Arch Chest Dis 2011; 76: 175-82.
14. Zanni MV, Grinspoon SK,. HIV-specific immune dysregulation and atherosclerosis. Curr HIV/AIDS Rep 2012; 9: 200-5.
15. Maniar A, Ellis C, Asmuth D, Pollard R, Rutledge J,. HIV infection and atherosclerosis: evaluating the drivers of inflammation. Eur J Prev Cardiol 2012; [Epub ahead of print].
16. d'Ettorre G, Paiardini M, Ceccarelli G, et al., HIV-associated immune activation: from bench to bedside. AIDS Res Hum Retroviruses 2011; 27: 355-64.
17. Brenchley JM, Price DA, Schacker TW, et al., Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-71.
18. Gonzalez VD, Falconer K, Blom KG, et al., High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus Type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009; 83: 11407-11.
19. Liebregts T, Adam B, Bredack C, et al., Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-20.
20. D'Agostino RB Sr,. Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis 2012; 205 (Suppl. 3): S362-7.
21. Serrano-Villar S, Estrada V, Gõmez-Garre D, et al., Diagnosis of subclinical atherosclerosis in HIV-infected patients: higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms. Eur J Prev Cardiol 2012; [Epub ahead of print].